News Earnings Uniworth International Limited Reports Q3FY26 Results with Net Loss of ₹39.45 LakhsUniworth International Limited Reports Q3FY26 Results with Net Loss of ₹39.45 Lakhs
Uniworth International Limited reported Q3FY26 standalone net loss of ₹39.45 lakhs versus ₹39.21 lakhs in Q3FY25, with no revenue generation and finance costs of ₹38.25 lakhs being the primary expense. Nine-month losses stood at ₹117.72 lakhs compared to ₹117.23 lakhs in the previous year, with EPS at (₹0.79) for the period.
*this image is generated using AI for illustrative purposes only.
Uniworth International Limited announced its unaudited financial results for the third quarter of FY26 ended December 31, 2025, revealing continued operational challenges with no revenue generation and sustained losses. The company reported these results following a Board meeting held on February 12, 2026, in compliance with SEBI regulations.
Financial Performance Overview
The company's standalone financial performance for Q3FY26 showed a net loss of ₹39.45 lakhs, marginally higher than the ₹39.21 lakhs loss recorded in the corresponding quarter of the previous year. The consolidated results reflected a net loss of ₹39.47 lakhs for the current quarter.
| Metric | Q3FY26 | Q3FY25 | Change |
|---|---|---|---|
| Revenue from Operations | - | - | - |
| Total Expenses | ₹39.45 lakhs | ₹39.21 lakhs | +0.61% |
| Net Loss | ₹39.45 lakhs | ₹39.21 lakhs | +0.61% |
| EPS | (₹0.26) | (₹0.26) | - |
Expense Analysis
The company's expense structure remained concentrated in finance costs, which constituted the largest component at ₹38.25 lakhs for Q3FY26, unchanged from the previous year's corresponding quarter. Employee benefit expenses remained stable at ₹0.51 lakhs, while other expenses increased to ₹0.70 lakhs from ₹0.45 lakhs in the previous year.
Nine-Month Performance
For the nine-month period ended December 31, 2025, Uniworth International reported a standalone net loss of ₹117.72 lakhs compared to ₹117.23 lakhs in the corresponding period of the previous year. The consolidated nine-month loss stood at ₹117.74 lakhs. Finance costs for the nine-month period totaled ₹114.74 lakhs, representing the primary expense component.
| Period | Nine Months FY26 | Nine Months FY25 | Change |
|---|---|---|---|
| Net Loss (Standalone) | ₹117.72 lakhs | ₹117.23 lakhs | +0.42% |
| Net Loss (Consolidated) | ₹117.74 lakhs | ₹117.31 lakhs | +0.37% |
| EPS | (₹0.79) | (₹0.79) | - |
Key Financial Highlights
• Share Capital: The company maintained a paid-up equity share capital of ₹1,490.00 lakhs with shares of ₹10 each • Subsidiary Operations: Uniworth Biotech Limited, a 98.60% subsidiary, reported minimal activity with nil revenue and ₹0.02 lakhs net loss • No Revenue Generation: The company continued to report zero revenue from operations across all reported periods • Consistent Loss Pattern: The loss figures remained relatively stable compared to previous year periods
Regulatory Compliance and Auditor Notes
The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI regulations. The auditors, Khandelwal Ray & Co., highlighted several provisions not considered in the accounts, including trade receivables of ₹3,010.57 lakhs, other financial assets of ₹227.73 lakhs, and miscellaneous advances of ₹52.70 lakhs that remain doubtful of recovery. The company has not recognized deferred tax assets due to consistent losses and uncertainty regarding future profits.
15
